Andreas Glenthøj: New Sickle Cell Trait Data in UpToDate
Andreas Glenthøj, Consultant Hematologist, Head of the Danish Red Blood Cell Center at Rigshospitalet, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in ASH Blood, adding:
“From publication to clinical guidance in less than two weeks.
Not all research changes clinical practice.
For decades, UpToDate has been my preferred source of rapid clinical guidance.
I am therefore honored to see our work on sickle cell trait at the Danish Red Blood Cell Center at Rigshospitalet incorporated into UpToDate less than two weeks after its publication in Blood, the flagship journal of the American Society of Hematology.
Sickle cell trait affects approximately 300 million individuals worldwide.
In a study of almost 468,000 genotyped individuals from the general population, we found no overall increased risk of premature death or major CVD among individuals with sickle cell trait.
By identifying carriers through consecutive genetic sequencing of the entire study population, rather than hospital diagnoses, we reduced the risk of studying a selected patient population.
We did, however, identify increased risks of diabetes, CKD, and hypertension, highlighting areas for continued clinical attention and research.
Thanks to professors Eliot Vichinsky and Michael DeBaun for noticing our paper and incorporating the findings into the UpToDate chapter on sickle cell trait (see link in comment).
A special thanks to all my co-authors, Shoaib Afzal, Shaodong Wei, Jesper Petersen, and particularly to first author Marie Warny and senior author Jens Helby.
Finally, our sincere thanks to the nearly 500,000 participants in the UK Biobank, whose contributions made this research possible.”
Title: No overall increased risk of death in individuals with sickle cell trait: a study of 467 779 general population adults
Authors: Marie Warny, Andreas Glenthøj, Shoaib Afzal, Shaodong Wei, Jesper Petersen, Jens Helby
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 16:53Flora Peyvandi: A New Approach to Coagulation with Bispecific Antibodies
-
Sep 10, 2026, 16:52Francisco Chacón-Lozsán: Perhaps We Are Treating ‘Sepsis’ When We Should Be Treating an Immune Phenotype
-
Sep 10, 2026, 16:46Aswin K Mohan: HLA Beyond Histocompatibility – Redefining Immune Recognition in Modern Medicine
-
Sep 10, 2026, 16:40Satyam Arora: Pediatric Apheresis – When Every Millilitre Matters
-
Sep 10, 2026, 16:39Marco Moscarelli: When CT Reveals Thrombosis After TAVI
-
Sep 10, 2026, 16:23Antonio Paul: When a Low Platelet Count Does Not Mean Weak Clotting
-
Sep 10, 2026, 16:12Balancing Thrombosis and Bleeding in Antiphospholipid Syndrome
-
Sep 10, 2026, 16:07Miguel Teran: Why ROTEM Will Redefine Major Bleeding Management
-
Sep 10, 2026, 16:04Isaac Okello: Where Skyline Meets Savannah – Quiet Moments at GASCDO in Nairobi